{"id":533,"date":"2023-03-06T23:58:10","date_gmt":"2023-03-06T23:58:10","guid":{"rendered":"https:\/\/furtherpr.com\/?p=533"},"modified":"2023-03-06T23:58:10","modified_gmt":"2023-03-06T23:58:10","slug":"eyepoint-pharma-takes-20-7m-intangible-impairment-charge-in-q4-shares-pipeline-update-expects-cash-runway-into-2024","status":"publish","type":"post","link":"https:\/\/furtherpr.com\/index.php\/2023\/03\/06\/eyepoint-pharma-takes-20-7m-intangible-impairment-charge-in-q4-shares-pipeline-update-expects-cash-runway-into-2024\/","title":{"rendered":"EyePoint Pharma Takes $20.7M Intangible Impairment Charge In Q4, Shares Pipeline Update, Expects Cash Runway Into 2024"},"content":{"rendered":"\n<p>Original story: <a href=\"https:\/\/www.benzinga.com\/general\/biotech\/23\/03\/31160136\/eyepoint-pharma-posts-deeper-losses-for-q4-expects-cash-runway-into-2024\">https:\/\/www.benzinga.com\/general\/biotech\/23\/03\/31160136\/eyepoint-pharma-posts-deeper-losses-for-q4-expects-cash-runway-into-2024<\/a><\/p>\n\n\n\n<p>by <a href=\"https:\/\/www.benzinga.com\/author\/vandana-singh\">Vandana Singh<\/a>, Benzinga Editor<\/p>\n\n\n\n<p>March 2, 2023 7:01 AM<\/p>\n\n\n\n<ul>\n<li><strong>EyePoint Pharmaceuticals Inc<\/strong>&nbsp;<a href=\"https:\/\/www.benzinga.com\/quote\/eypt\" rel=\"noreferrer noopener\" target=\"_blank\"><\/a><a href=\"https:\/\/www.benzinga.com\/quote\/eypt\" rel=\"noreferrer noopener\" target=\"_blank\"><\/a><a href=\"https:\/\/www.benzinga.com\/quote\/eypt\" rel=\"noreferrer noopener\" target=\"_blank\"><\/a><a href=\"https:\/\/www.benzinga.com\/quote\/eypt\" rel=\"noreferrer noopener\" target=\"_blank\"><strong>EYPT<\/strong><strong>-0.61%<\/strong>+ Free Alerts<\/a>&nbsp;has reported Q4 revenues of $10.5 million, down 8.8% Y\/Y, almost in line with the consensus of $10.40 million.<\/li>\n\n\n\n<li>Non-operating income totaled $0.3 million, and the net loss was $(43.5) million, or ($1.16) per share, compared to a net loss of $(19.4) million, or ($0.59) per share, for the prior year period. Wall Street&#8217;s estimate was an EPS loss of $(0.61).<\/li>\n\n\n\n<li>Net product revenue for Yutiq was $9.0 million, a 55% Y\/Y increase, with customer demand of approximately 980 units.<\/li>\n\n\n\n<li>Cash, cash equivalents, and investments in marketable securities totaled $144.6 million, with cash runway projected into 2H of 2024.<\/li>\n\n\n\n<li>Most recently, EyePoint and&nbsp;<strong>Rallybio Corporation<\/strong>&nbsp;<a href=\"https:\/\/www.benzinga.com\/quote\/rlyb\" rel=\"noreferrer noopener\" target=\"_blank\"><\/a><a href=\"https:\/\/www.benzinga.com\/quote\/rlyb\" rel=\"noreferrer noopener\" target=\"_blank\"><\/a><a href=\"https:\/\/www.benzinga.com\/quote\/rlyb\" rel=\"noreferrer noopener\" target=\"_blank\"><\/a><a href=\"https:\/\/www.benzinga.com\/quote\/rlyb\" rel=\"noreferrer noopener\" target=\"_blank\"><strong>RLYB<\/strong><strong>+10.3%<\/strong>+ Free Alerts<\/a>&nbsp;<a href=\"https:\/\/www.benzinga.com\/pressreleases\/23\/02\/g31065831\/eyepoint-and-rallybio-announce-research-collaboration-to-evaluate-rallybios-inhibitor-of-complemen\" target=\"_blank\" rel=\"noreferrer noopener\">announced a research collaboration<\/a>&nbsp;to evaluate sustained delivery of Rallybio&#8217;s inhibitor of complement component 5 using EyePoint&#8217;s proprietary Durasert technology for sustained intraocular drug delivery.&nbsp;<\/li>\n\n\n\n<li>The initial focus will be geographic atrophy.<\/li>\n\n\n\n<li><strong>Pipeline Update:<\/strong>\n<ul>\n<li>Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD remains on track, with topline data anticipated by year-end 2023.<\/li>\n\n\n\n<li>Phase 2 PAVIA trial for EYP-1901 in non-proliferative diabetic retinopathy is on track, with enrollment completion anticipated in 4Q 2023.<\/li>\n\n\n\n<li>The company looks forward to presenting preclinical data on the observed neuroprotective effect of vorolanib in a mouse model of retinal detachment at the upcoming 2023 ARVO Annual Meeting in April.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Price Action:<\/strong>&nbsp;EYPT shares closed at $3.17 on Wednesday.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Original story: https:\/\/www.benzinga.com\/general\/biotech\/23\/03\/31160136\/eyepoint-pharma-posts-deeper-losses-for-q4-expects-cash-runway-into-2024 by Vandana Singh, Benzinga Editor March 2, 2023 7:01 AM<\/p>\n","protected":false},"author":1,"featured_media":534,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_mi_skip_tracking":false},"categories":[1],"tags":[],"aioseo_notices":[],"rttpg_featured_image_url":{"full":["https:\/\/furtherpr.com\/wp-content\/uploads\/2023\/03\/EyePoint_Pharmaceuticals_Logo-scaled.jpg",2560,1341,false],"landscape":["https:\/\/furtherpr.com\/wp-content\/uploads\/2023\/03\/EyePoint_Pharmaceuticals_Logo-scaled.jpg",2560,1341,false],"portraits":["https:\/\/furtherpr.com\/wp-content\/uploads\/2023\/03\/EyePoint_Pharmaceuticals_Logo-scaled.jpg",2560,1341,false],"thumbnail":["https:\/\/furtherpr.com\/wp-content\/uploads\/2023\/03\/EyePoint_Pharmaceuticals_Logo-150x150.jpg",150,150,true],"medium":["https:\/\/furtherpr.com\/wp-content\/uploads\/2023\/03\/EyePoint_Pharmaceuticals_Logo-300x157.jpg",300,157,true],"large":["https:\/\/furtherpr.com\/wp-content\/uploads\/2023\/03\/EyePoint_Pharmaceuticals_Logo-1024x536.jpg",800,419,true],"1536x1536":["https:\/\/furtherpr.com\/wp-content\/uploads\/2023\/03\/EyePoint_Pharmaceuticals_Logo-1536x804.jpg",1536,804,true],"2048x2048":["https:\/\/furtherpr.com\/wp-content\/uploads\/2023\/03\/EyePoint_Pharmaceuticals_Logo-2048x1073.jpg",2048,1073,true]},"rttpg_author":{"display_name":"prfurther","author_link":"https:\/\/furtherpr.com\/index.php\/author\/prfurther\/"},"rttpg_comment":5,"rttpg_category":"<a href=\"https:\/\/furtherpr.com\/index.php\/category\/uncategorized\/\" rel=\"category tag\">Uncategorized<\/a>","rttpg_excerpt":"Original story: https:\/\/www.benzinga.com\/general\/biotech\/23\/03\/31160136\/eyepoint-pharma-posts-deeper-losses-for-q4-expects-cash-runway-into-2024 by Vandana Singh, Benzinga Editor March 2, 2023 7:01 AM","_links":{"self":[{"href":"https:\/\/furtherpr.com\/index.php\/wp-json\/wp\/v2\/posts\/533"}],"collection":[{"href":"https:\/\/furtherpr.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/furtherpr.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/furtherpr.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/furtherpr.com\/index.php\/wp-json\/wp\/v2\/comments?post=533"}],"version-history":[{"count":1,"href":"https:\/\/furtherpr.com\/index.php\/wp-json\/wp\/v2\/posts\/533\/revisions"}],"predecessor-version":[{"id":535,"href":"https:\/\/furtherpr.com\/index.php\/wp-json\/wp\/v2\/posts\/533\/revisions\/535"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/furtherpr.com\/index.php\/wp-json\/wp\/v2\/media\/534"}],"wp:attachment":[{"href":"https:\/\/furtherpr.com\/index.php\/wp-json\/wp\/v2\/media?parent=533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/furtherpr.com\/index.php\/wp-json\/wp\/v2\/categories?post=533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/furtherpr.com\/index.php\/wp-json\/wp\/v2\/tags?post=533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}